🧬Tidera Health
⚕️

Educational tool only. Does not confirm eligibility or provide medical advice. Always consult your physician before pursuing any trial.

OncologyICD-10: C91

Find Recruiting Clinical Trials for Leukemia

Search AML, CLL, CML, ALL, and MDS leukemia trials — matched to your leukemia type, cytogenetics, and prior therapy.

🔍 Search Leukemia Trials →

About Leukemia

Leukemia encompasses a group of blood cancers originating in bone marrow and blood-forming tissues. The four main types are: acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), and acute lymphoblastic leukemia (ALL). Each has distinct biology, treatment paradigms, and trial landscapes. CML has been transformed by BCR-ABL tyrosine kinase inhibitors (imatinib and successors). CLL has similarly been transformed by BTK inhibitors (ibrutinib, acalabrutinib) and venetoclax. AML and ALL remain areas of intense trial activity.

What Types of Leukemia Clinical Trials Exist?

Leukemia trials are among the most molecularly stratified in oncology. AML trials test new FLT3 inhibitors, IDH1/2 inhibitors, menin inhibitors (for KMT2A-rearranged and NPM1-mutant AML), venetoclax combinations, and novel induction regimens. CLL trials test next-generation BTK inhibitors (pirtobrutinib — non-covalent), venetoclax combinations, CAR-T cell therapies, and fixed-duration treatment protocols. ALL trials test blinatumomab combinations, inotuzumab ozogamicin, CAR-T (tisagenlecleucel), and MRD-guided therapy. Molecular and cytogenetic profile (FLT3-ITD, NPM1, IDH1/2, BTK mutation for ibrutinib resistance, Philadelphia chromosome) are critical eligibility determinants.

Find Recruiting Leukemia Trials Near You

Enter your profile and we'll search ClinicalTrials.gov in real time — matching trials to your age, location, and treatment history. Free, no account required.

Search Leukemia Trials →

Data from ClinicalTrials.gov · Updated in real time · Educational use only

Frequently Asked Questions

What clinical trials are available for leukemia?▾
Recruiting leukemia trials vary significantly by type. AML: menin inhibitors, FLT3 inhibitors, venetoclax combinations, novel antibody-drug conjugates. CLL: non-covalent BTK inhibitors, venetoclax + obinutuzumab optimization, CAR-T. AML/MDS: hypomethylating agent combinations. ALL: blinatumomab, inotuzumab, CAR-T, BCR-ABL inhibitors for Ph+ ALL.
How does molecular testing affect leukemia trial eligibility?▾
Molecular testing is essential for leukemia trial eligibility. For AML: FLT3-ITD/TKD, NPM1, IDH1, IDH2, KMT2A rearrangement, and TP53 mutations all affect eligibility for targeted trials. For CLL: IGHV mutation status, del(17p), TP53 mutation, and BTK/BCL2 resistance mutations determine treatment and trial options. Complete molecular profiling at diagnosis and relapse is critical.
What is MRD (minimal residual disease) testing in leukemia trials?▾
MRD measures the depth of treatment response — whether leukemia cells are undetectable at the level of 1 in 10,000 or 1 in 100,000 cells using highly sensitive PCR or flow cytometry. MRD negativity is increasingly used as a surrogate endpoint in trials and as a guide for treatment duration in CLL fixed-duration trials. Some trials specifically enroll MRD-positive patients after standard therapy.

Related Conditions

LymphomaBreast CancerLung Cancer

Data source: All clinical trial information is sourced from ClinicalTrials.gov, the official U.S. registry maintained by the National Library of Medicine. Tidera Health is an independent educational platform and is not affiliated with ClinicalTrials.gov or the National Library of Medicine. Always verify trial details directly with the research coordinator or your physician.